Compare ICON & DCOY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ICON | DCOY |
|---|---|---|
| Founded | 2023 | N/A |
| Country | Greece | United States |
| Employees | N/A | 11 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5M | 4.2M |
| IPO Year | N/A | N/A |
| Metric | ICON | DCOY |
|---|---|---|
| Price | $0.85 | $6.11 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $30.00 |
| AVG Volume (30 Days) | ★ 112.8K | 12.6K |
| Earning Date | 02-24-2026 | 05-16-2026 |
| Dividend Yield | ★ 4754.20% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $22.33 | N/A |
| Revenue Next Year | $23.70 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.54 | $0.53 |
| 52 Week High | $4.23 | $9.57 |
| Indicator | ICON | DCOY |
|---|---|---|
| Relative Strength Index (RSI) | 31.34 | 47.85 |
| Support Level | $0.81 | $4.98 |
| Resistance Level | $1.24 | $6.47 |
| Average True Range (ATR) | 0.08 | 0.78 |
| MACD | -0.02 | -0.08 |
| Stochastic Oscillator | 15.70 | 36.33 |
Icon Energy Corp is a growth-oriented shipping company providing seaborne transportation services for dry bulk cargoes via its fleet of oceangoing vessels. The company generates its revenues by chartering its vessels to regional and international dry bulk operators, commodity traders and end users. The cargos carried by the company are Grains, Minerals, Iron Ore, Coal and Bauxite.
Decoy Therapeutics Inc is a pre-clinical stage biotechnology company focused on advancing its pipeline of peptide conjugate therapeutics engineered through its proprietary IMP3ACT platform. The IMP3ACT platform represents a paradigm shift in peptide conjugate drug discovery and manufacturing, leveraging machine learning (ML) and artificial intelligence (AI" tools alongside high-speed synthesis techniques to rapidly engineer, optimize and manufacture peptide conjugates that target serious unmet medical needs. The company manages its business in one operating segment, focused on the discovery and development therapeutics for patients with high, unmet medical needs. Its pipeline programs include: Pan-Coronavirus; and Tripledemic.